Board Committee Changes

Regulatory News Service

26 June 2018 07:00 BST

AstraZeneca PLC (the Company) today announced the following Board Committee changes.

Science Committee:

With effect from 1 July 2018, Nazneen Rahman will become permanent Chairman of the Science Committee.  Professor Rahman joined the Science Committee on her appointment as a Director on 1 June 2017 and has been interim Chairman of the Committee since November 2017.

Audit Committee:

With effect from 30 June 2018, Shriti Vadera will step down as a member of the Audit Committee.  As previously announced, Shriti Vadera has informed the Board that she will retire as a Director by 31 December 2018.  With effect from 1 November 2018, Deborah DiSanzo will become a member of the Audit Committee.

Remuneration Committee:

With effect from 1 July 2018, Sheri McCoy will become a member of the Remuneration Committee.

Nomination and Governance Committee:

With effect from 1 July 2018, Nazneen Rahman will become a member of the Nomination and Governance Committee.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 


CONTACTS

     

Media Relations

 

 

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Gonzalo Viña

UK/Global

+44 203 749 5916

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

     

Investor Relations

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Josie Afolabi

 

+44 203 749 5631

Craig Marks

Finance; Fixed Income; M&A

+44 7881 615 764

Henry Wheeler

Oncology

+44 203 749 5797

Mitchell Chan

Oncology; Other

+1 240 477 3771

Christer Gruvris

Brilinta; Diabetes

+44 203 749 5711

Nick Stone

Respiratory; Renal

+44 203 749 5716

Jennifer Kretzmann

Retail Investors

+44 203 749 5824

US toll-free

 

+1 866 381 7277

 

 

 

Adrian Kemp
Company Secretary
AstraZeneca PLC
 

tags

  • Regulatory